----

----

| [X]                                                              | ANNUAL      REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF      1934     |
|------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| For      the fiscal year ended: December 31, 2007                |
| OR                                                               |
|                                                             |
| [   ]                                             | TRANSITION      REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF      1934 |
| For      the transition period from ___________ to _____________ |
| Commission      File Number: 001-31584                           |

| Delaware                                                                |   | 23-3057155                                       |
|-------------------------------------------------------------------------|--------|--------------------------------------------------|
| (State or Other Jurisdiction      ofIncorporation or      Organization) |   | (I.R.S.      EmployerIdentification      Number) |

| 4      Hillman Drive, Suite 130, Chadds Ford, Pennsylvania |   | 19317         |
|------------------------------------------------------------|--------|---------------|
| (Address of principal executive      offices)              |   | (Zip    Code) |

| Large      accelerated filer [   ]                     | Accelerated      filer                    [X] |
|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Non-Acclerated      filer    [   ] | Smaller      reporting  company  [   ]                                                                                   |

----

----

| Item      10. | Directors,      Executive Officers and CorporateGovernance |
|---------------|------------------------------------------------------------|

| Name                          |   | Age    |   | Position                                                  |
|-------------------------------|--------|--------|--------|-----------------------------------------------------------|
|                          |   |   |   |                                                      |
| Haywood      D. Cochrane, Jr. |   | 59     |   | Vice-Chairman      and Director                           |
| Raymond      J. Fabius, M.D.  |   | 54     |   | President,      Chief Medical Officer and Director        |
| Philip      D. Green          |   | 57     |   | Director                                                  |
| Gail      F. Lieberman        |   | 64     |   | Director                                                  |
| Frank      A. Martin          |   | 57     |   | Chairman      and Director                                |
| Gerald      D. Mintz          |   | 55     |   | Director                                                  |
| David      Nash, M.D.         |   | 52     |   | Director                                                  |
| Jack      A. Smith            |   | 72     |   | Director                                                  |
| R.      Dixon Thayer          |   | 56     |   | Chief      Executive Officer and Director                 |
| Peter      Hotz               |   | 47     |   | Executive      Vice President and Chief Operating Officer |
| Bradley      S. Wear          |   | 50     |   | Senior      Vice President and Chief Financial Officer    |
| Yuri      Rozenfeld           |   | 39     |   | Senior      Vice President, General Counsel andSecretary  |

----

----

----

----

| Item      11. | Executive      Compensation |
|---------------|-----------------------------|

| ·   | Base      salaries sufficient to attract, retain and motivate key executives and      provide competitive compensationopportunities. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Annual      bonus and incentive programs that provide opportunity for significant      increases in compensation based on meeting or exceeding pre-determined      performance targets. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Substantial      long-term compensation to reward increases in the stockholder value of      I-trax. |
|--------------------|------------------------------------------------------------------------------------------------------|

----

----

----

|   Name and Principal Position                   |   Year |   | Salary($) |    |   | Bonus($)(1) |   |    | StockAwards($)(2) |   |   | OptionAwards($)(2) |   |   | All      OtherCompensation($)(3) |    |   | Total($) |   |
|-----------------------------------------------------------|------------------|--------|-----------|---------|--------|-------------|--------|---------|-------------------|--------|--------|--------------------|--------|--------|----------------------------------|---------|--------|----------|--------|
| R.      Dixon Thayer                                      | 2007             |   | $         | 363,022 |   |        | $      | 181,511 |              |   |   | —            |   |   | $                                | 225,077 |   |     | $      | 5,260 |   |   | $ | 774,870 |   |
| Chief      Executive Officer                              | 2006             |   | $         | 300,000 |   |        | $      | 100,000 |              |   | $      | 79,600             |   |   | $                                | 151,542 |   |     | $      | 700 |   |   | $ | 631,843 |   |
| Frank      A. Martin                                      | 2007             |   | $         | 276,349 |   |        | $      | 108,175 |              |   |   | —            |   |   | $                                | 63,773  |   |     | $      | 3,395 |   |   | $ | 451,692 |   |
| Chairman                                                  | 2006             |   | $         | 250,000 |   |        | $      | 125,000 |              |   |   | —            |   |   | $                                | 41,089  |   |     | $      | 3,448 |   |   | $ | 419,537 |   |
| Raymond      J.  Fabius, M.D.         | 2007             |   | $         | 348,249 |   |        | $      | 125,000 |              |   |   | —            |   |   | $                                | 187,784 |   |     | $      | 5,537 |   |   | $ | 666,570 |   |
| President      and Chief                                  | 2006             |   | $         | 302,405 |   |        | $      | 75,000  |              |   | $      | 53,730             |   |   | $                                | 140,726 |   |     | $      | 5,604 |   |   | $ | 577,465 |   |
| Medical      Officer                                      |             |   |      |    |   |        |   |    |              |   |   |               |   |   |                             |    |   |     |   |   |   |   |   |   |   |
| Yuri      Rozenfeld                                       | 2007             |   | $         | 206,418 |   |        | $      | 61,925  |              |   |   | —            |   |   | $                                | 46,732  |   |     | $      | 4,641 |   |   | $ | 319,716 |   |
| Senior      Vice President,                               | 2006             |   | $         | 195,000 |   |        | $      | 58,500  |              |   |   | —            |   |   | $                                | 45,395  |   |     | $      | 3,140 |   |   | $ | 302,035 |   |
| General      Counsel and Secretary                        |             |   |      |    |   |        |   |    |              |   |   |               |   |   |                             |    |   |     |   |   |   |   |   |   |   |
| Bradley      S. Wear                                      | 2007             |   | $         | 77,538  |   |        | $      | 31,015  |              |   |   | —            |   |   | $                                | 25,122  |   |     | $      | 66 |   |   | $ | 133,741 |   |
| Senior      Vice President and Chief Financial Officer(4) |             |   |      |    |   |        |   |    |              |   |   |               |   |   |                             |    |   |     |   |   |   |   |   |   |   |
| David      R. Bock                                        | 2007             |   | $         | 257,028 |   |        | $      | 68,450  |              |   |   | —            |   |   | $                                | 134,820 |   |     | $      | 7,336 |   |   | $ | 467,634 |   |
| Former      Executive Vice                                | 2006             |   | $         | 250,000 |   |        | $      | 100,000 |              |   |   | —            |   |   | $                                | 151,627 |   |     | $      | 5,990 |   |   | $ | 507,617 |   |
| President      and Chief Financial Officer(5)             |             |   |      |    |   |        |   |    |              |   |   |               |   |   |                             |    |   |     |   |   |   |   |   |   |   |

| (1)    | “Bonus”      consists of cash bonuses earned in the fiscal year      identified.  See “Compensation Discussion and Analysis” section      of this Amendment to Annual Report on Form 10-K.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| (2)    | Represents      value of option awards vested in 2006 calculated in accordance with the      fair value recognition provisions of Statement of Financial Accounting      Standards (SFAS) No. 123 (revised 2004), Share-BasedPayment, and charged to      I-trax’s      operations in 2007.  For further details, including I-trax’s      assumptions in calculating the fair value, please see Note 1, Summary of Significant      Accounting Policies, and Note 11, Share Based      Compensation, to I-trax’s financial statements included in I-trax’s      Annual Report on Form 10-K for the period ended December 31,      2007 filed on March 17, 2008. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| (3)    | “All      other compensation” includes I-trax’s 401(k) match and group term life      insurance premiums.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| (4)    | Mr. Wear      became the Chief Financial Officer of I-trax effective September 1,      2007.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| (5)    | Mr. Bock      stepped down as the Chief Financial Officer of I-trax effective      September 1, 2007.  Mr. Bock’s bonus for 2007 was paid      on April 25, 2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

----

|     Name            |   |    Grant Date(1) |    |   | All      Other OptionAwards:      Numberof      SecuritiesUnderlyingOptions (#)(1) |    |    | Exercise      or BasePrice      of OptionAwards($ /Sh)(2) |   |   | Grant      Date FairValue      of Stockand      OptionAwards |   |
|-----------------------------------------|--------|---------------------------------|---------|--------|-----------------------------------------------------------------------------------------|---------|---------|-----------------------------------------------------------|--------|--------|--------------------------------------------------------------|--------|
| R.      Dixon Thayer                    |   |                            | — |   |                                                                                    |    | — |                                                      |   |   | —                                                      |   |   |   | — |   |
| Frank      A. Martin                    |   |                            | — |   |                                                                                    |    | — |                                                      |   |   | —                                                      |   |   |   | — |   |
| Raymond      J. Fabius, M.D.  |   |                            | — |   |                                                                                    |    | — |                                                      |   |   | —                                                      |   |   |   | — |   |
| Yuri      Rozenfeld                     |   | 8/13/2007                       |    |   |                                                                                    | 23,166  |    |                                                      | $      | 3.60   |                                                         |   | $ | 48,151 |   |
| Bradley      S. Wear                    |   | 9/10/2007                       |    |   |                                                                                    | 125,000 |    |                                                      | $      | 3.25   |                                                         |   | $ | 234,000 |   |
| David      R. Bock                      |   |                            | — |   |                                                                                    |    | — |                                                      |   |   | —                                                      |   |   |   | — |   |

| (1)    | The      options vest in three equal installments on each of the first, second, and      third anniversaries of the grant date. |
|--------|---------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                            |
| (2)    | The      exercise price equals the closing price of I-trax common stock on the date      of grant.                              |

----

|                                               |                             |   | Number      of Securities   |    |   |          |   |       |
|----------------------------------------------------|----------------------------------|--------|-----------------------------|---------|--------|---------------|--------|------------|
|                                               |                             |   | Underlying      Unexercised |    |   | Option        |   | Option     |
|                                               |                             |   | Options (#)            |    |   | Exercise      |   | Expiration |
| Name                                               | Grant Date(1)                    |   | Exercisable                 |    |   | Unexercisable |   |       | Price ($) |   | Date |
| R.      Dixon Thayer                               | 5/9/2003                         |   |                        | 40,000  |   |          |   | —    |   |   | $ | 1.51 |   | 5/8/2013 |
|                                               | 2/14/2005                        |   |                        | 304,078 |   |          |   | 25,000     |   |   | $ | 1.41 |   | 2/13/2015 |
|                                               | 2/14/2005                        |   |                        | 70,922  |   |          |   | —    |   |   | $ | 1.40 |   | 2/13/2015 |
|                                               |     8/9/2006 |   |                        | 74,373  |   |          |   | 148,747    |   |   | $ | 3.09 |   |     8/8/2016 |
| Frank      A. Martin                               | 4/10/2001                        |   |                        | 70,000  |   |          |   | —    |   |   | $ | 2.75 |   | 4/9/2011 |
|                                               | 12/23/2002                       |   |                        | 1,750   |   |          |   | —    |   |   | $ | 3.00 |   | 12/22/2012 |
|                                               | 5/9/2003                         |   |                        | 100,000 |   |          |   | —    |   |   | $ | 1.51 |   | 5/8/2013 |
|                                               |     8/9/2006 |   |                        | 35,417  |   |          |   | 70,833     |   |   | $ | 3.09 |   |     8/8/2016 |
| Raymond      J.  Fabius, M.D.  | 5/17/2005                        |   |                        | 137,978 |   |          |   | 19,716     |   |   | $ | 1.40 |   | 5/16/2015 |
|                                               | 5/17/2005                        |   |                        | 212,018 |   |          |   | 30,288     |   |   | $ | 1.56 |   | 5/16/2015 |
|                                               |     8/9/2006 |   |                        | 48,827  |   |          |   | 97,653     |   |   | $ | 3.09 |   |     8/8/2016 |
| Yuri      Rozenfeld                                | 4/10/2001                        |   |                        | 40,000  |   |          |   | —    |   |   | $ | 2.75 |   | 4/9/2011 |
|                                               | 12/23/2002                       |   |                        | 1,300   |   |          |   | —    |   |   | $ | 3.00 |   | 12/22/2012 |
|                                               | 1/4/2002                         |   |                        | 10,000  |   |          |   | —    |   |   | $ | 6.25 |   | 1/3/2012 |
|                                               | 5/9/2003                         |   |                        | 50,000  |   |          |   | —    |   |   | $ | 1.51 |   | 5/8/2013 |
|                                               | 2/2/2005                         |   |                        | 36,664  |   |          |   | 3,336      |   |   | $ | 1.40 |   | 2/1/2015 |
|                                               | 2/2/2005                         |   |                        | 60,000  |   |          |   | —    |   |   | $ | 1.40 |   | 2/1/2015 |
|                                               | 8/9/2006                         |   |                        | 9,750   |   |          |   | 19,500     |   |   | $ | 3.09 |   | 8/8/2016 |
|                                               |    8/14/2007      |   |                        | — |   |          |   | 23,166     |   |   | $ | 3.60 |   |    8/13/2017 |
| Bradley      S. Wear                               |    9/11/2007      |   |                        | — |   |          |   | 125,000    |   |   | $ | 3.25 |   |    9/10/2017 |
| David      R. Bock                                 | 5/9/2003                         |   |                        | 40,000  |   |          |   | —    |   |   | $ | 1.51 |   | 5/8/2013 |
|                                               | 2/2/2005                         |   |                        | 400,000 |   |          |   | —    |   |   | $ | 1.40 |   | 2/2/2015 |
|                                               | 8/9/2006                         |   |                        | 35,417  |   |          |   | 70,833     |   |   | $ | 3.09 |   | 8/8/2016 |

| (1) | The      options vest in three equal installments on each of the first, second, and      third anniversaries of the grantdate. |
|-----|--------------------------------------------------------------------------------------------------------------------------------|

----

|      Name              |      Benefit(1)(2) |   | Before      Changein      ControlTerminationw/o      Cause orfor      GoodReason |    |   | After      Changein      ControlTerminationw/o      Cause orfor      GoodReason |   |    |    VoluntaryTermination |   |   |     Death |   |   |     Disability |    |   |   ChangeinControl |   |
|-------------------------------------------------|---------------------------------------------|--------|----------------------------------------------------------------------------------|---------|--------|---------------------------------------------------------------------------------|--------|---------|----------------------------------------|--------|--------|-------------------------------|--------|--------|------------------------------------|---------|--------|-----------------------------|--------|
| R.      Dixon Thayer(3)                         | Salary                                      |   | $                                                                                | 772,479 |   |                                                                            | $      | 772,479 |                                   |   |   | —                       |   |   | $                                  | 32,187  |   |                        | $      | 32,187 |   |   | $ | 772,479 |   |
|                                            | Bonus                                       |   | $                                                                                | 331,511 |   |                                                                            | $      | 331,511 |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   | $ | 331,511 |   |
|                                            | Medical      anddental                      |   | $                                                                                | 32,029  |   |                                                                            | $      | 32,029  |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   | $ | 32,029 |   |
|                                            | Stock      optionsacceleration              |   |                                                                             | 53,500  |   |                                                                            |   | 53,500  |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   |   | 53,500 |   |
| Frank      A. Martin                            | Salary                                      |   | $                                                                                | 572,114 |   |                                                                            | $      | 572,114 |                                   |   |   | —                       |   |   | $                                  | 23,838  |   |                        | $      | 23,838 |   |   | $ | 572,114 |   |
|                                            | Bonus                                       |   | $                                                                                | 233,175 |   |                                                                            | $      | 233,175 |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   | $ | 233,175 |   |
|                                            | Medical      anddental                      |   | $                                                                                | 23,056  |   |                                                                            | $      | 23,056  |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   | $ | 23,056 |   |
|                                            | Stock      optionsacceleration              |   |                                                                             | — |   |                                                                            |   | — |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   |   | — |   |
| Raymond      J.  Fabius, M.D.(4) | Salary                                      |   | $                                                                                | 772,839 |   |                                                                            | $      | 772,839 |                                   |   |   | —                       |   |   | $                                  | 30,118  |   |                        | $      | 30,118 |   |   |   | — |   |
|                                            | Bonus                                       |   | $                                                                                | 250,000 |   |                                                                            | $      | 250,000 |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   |   | — |   |
|                                            | Medical      anddental                      |   | $                                                                                | 26,348  |   |                                                                            | $      | 26,348  |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   |   | — |   |
|                                            | Stock      optionsacceleration              |   |                                                                             | 102,662 |   |                                                                            |   | 102,662 |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   |   | 102,662 |   |
| Yuri      Rozenfeld                             | Salary                                      |   | $                                                                                | 210,625 |   |                                                                            | $      | 210,625 |                                   |   |   | —                       |   |   |                               | 17,552  |   |                        |   | 17,552 |   |   |   | — |   |
|                                            | Bonus                                       |   |                                                                             | — |   |                                                                            |   | — |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   |   | — |   |
|                                            | Medical      anddental                      |   |                                                                             | — |   |                                                                            |   | — |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   |   | — |   |
|                                            | Stock      optionsacceleration              |   |                                                                             | — |   |                                                                            |   | — |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   |   | — |   |
| Bradley      S. Wear                            | Salary                                      |   | $                                                                                | 240,000 |   |                                                                            | $      | 240,000 |                                   |   |   | —                       |   |   | $                                  | 20,000  |   |                        | $      | 20,000 |   |   |   | — |   |
|                                            | Bonus                                       |   |                                                                             | — |   |                                                                            |   | — |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   |   | — |   |
|                                            | Medical      anddental                      |   | $                                                                                | 14,065  |   |                                                                            | $      | 14,065  |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   |   | — |   |
|                                            | Stock      optionsacceleration              |   |                                                                             | — |   |                                                                            |   | — |                                   |   |   | —                       |   |   |                               | — |   |                        |   | — |   |   |   | — |   |

| (1)    | Amounts      reported with respect to “Medical and dental benefits” represent an      estimate of COBRA payments that I-trax is obligated to reimburse the named      executive officer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| (2)    | The      employment agreement with each named executive officer specifies that      options to acquire Common Shares granted to such executive and covered by      the employment agreement will accelerate upon a change in control of      I-trax. This provision does not apply to options not specifically      addressed in the employment agreement. Accordingly, amounts reported with      respect to “Stock options acceleration” represent the difference between      the exercise price of the options subject to acceleration and the      December 31, 2007 closing price for Common Shares, multiplied by the      number of options subject to acceleration. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| (3)    | If      Mr. Thayer dies or is disabled while on company business or      performing his duties under his employment agreement, Mr. Thayer’s      termination benefits will be as provided upon termination w/out cause or      for good reason. Under Mr. Thayer’s employment agreement, a change in      control constitutes good reason.                                                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| (4)    | If      any payment made to Dr. Fabius is deemed an “excess parachute      payment” within the meaning of Section 280G of the Internal Revenue      Code, I-trax must pay Dr. Fabius a “gross up” payment to compensate      Dr. Fabius for the amount of the applicable taxes. However, a      termination of Dr. Fabius’s employment in connection with a change in      control at December 31, 2007 would not trigger an “excess parachute      payment.”                                                                                                                                                         |

----

----

----

----

| Name                                |   | Fees      Earned or Paidin      Cash ($) |   |   | Option      Awards($)(1)(2) |   |      | All      OtherCompensation ($) |   |   | Total ($) |   |
|-------------------------------------|--------|-----------------------------------------------|--------|--------|-----------------------------|--------|-----------|-------------------------------------|--------|--------|----------------|--------|
| Haywood      D. Cochrane, Jr.  |   | $                                             | 26,000 |   |                        |   | —   |                                |   |   | —        |   |   | $ | 26,000 |   |
| Philip      D. Green                |   | $                                             | 31,750 |   |                        | $      | 11,777.00 |                                |   |   | —        |   |   | $ | 43,527.00 |   |
| Gail      F. Lieberman              |   | $                                             | 48,000 |   |                        | $      | 18,395.00 |                                |   |   | —        |   |   | $ | 66,395.00 |   |
| Gerald      D. Mintz                |   | $                                             | 33,000 |   |                        | $      | 23,529.00 |                                |   |   | —        |   |   | $ | 56,529.00 |   |
| David      B. Nash, M.D.  |   | $                                             | 26,000 |   |                        | $      | 11,764.00 |                                |   |   | —        |   |   | $ | 37,764.00 |   |
| Jack      A. Smith                  |   | $                                             | 32,500 |   |                        | $      | 35,693.00 |                                |   |   | —        |   |   | $ | 68,193.00 |   |

| (1)    | Represents      value of option awards vested in 2007 calculated in accordance with the      fair value recognition provisions of Statement of Financial Accounting      Standards No. 123 (revised 2004), Share-BasedPayment (“SFAS 123R”), and      charged to I-trax’s operations in 2007. For further details, including      I-trax’s assumptions in calculating the fair value, please see      Note 1, Summary of      SignificantAccounting Policies,      and Note 11, Share      BasedCompensation, to      I-trax’s financial statements included in I-trax’s Annual Report on      Form 10-K for the period ended December 31, 2007 filed on      March 17, 2008.                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| (2)    | The      named directors hold options to acquire shares of common stock as follows:      Mr. Cochrane — 300,000 shares; Mr. Green —      102,880 shares; Ms. Lieberman — 80,000 shares;      Mr. Mintz — 80,000 shares; Dr. Nash — 60,000; and      Mr. Smith — 40,000 shares. Mr. Cochrane’s options were      received in connection with his services as an executive officer of      I-trax. These options remain outstanding and continue to vest in      consideration of Mr. Cochrane’s continued service as a director of      I-trax. In accordance with the fair value recognition provisions of      SFAS 123R, for 2007, $90,477 in share-based compensation expense was      recognized for option awards that Mr. Cochrane had previously      received in connection with his services as an executive officer of      I-trax. In addition, pursuant to the terms of his original employment      agreement, Mr. Cochrane received $8,377 in medical and dental      benefits from I-trax in 2007. |

----

| Item      12. | Security      Ownership of Certain Beneficial Owners and Management and Related      Stockholder Matters |
|---------------|----------------------------------------------------------------------------------------------------------|

| Plan      Category                                                       | Number      of shares of common stock issuable upon the exercise of outstanding      options, warrants and rights | Weighted      average exercise price of outstanding options, warrants and      rights | Number      of shares of common stock available for issuance under equity compensation      plans (excluding shares of common stock reflected in first      column) |
|--------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Equity      compensation plans approved      by security holders (1)     | 4,567,323                                                                                                         | $2.20                                                                                 | 31,852                                                                                                                                                              |
| Equity      compensation plans not approved      by security holders (2) | 1,750,755                                                                                                         | $2.99                                                                                 |           --                                                                                                      |
| Totals:                                                                  | 6,318,078                                                                                                         | $2.42                                                                                 |  31,852                                                                                                                                                        |

| (1) | Represents      shares issuable upon exercise of options under our 2000 and 2001 Equity      Compensation Plans.  The number of shares authorized for      issuance under the 2001 Plan increases automatically on the first day of      each year by 300,000 shares.  Generally, options granted under      the 2000 and 2001 Plans vest over a period of three years with respect to      grants made to employees and consultants and over a period of two years      with respect to options granted to directors.  Exercise prices      are established with reference to our common stock’s market      price. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Includes      options to acquire an aggregate of 163,000 shares granted      outside of our 2000 and 2001 Equity Compensation Plans and warrants to      acquire an additional 1,587,755 shares.  Options      granted outside of our 2000 and 2001 Plans have terms similar to options      granted pursuant to the Plans, including exercise prices established with      reference to our common stock’s market price and vesting and exercise      terms.  Warrants are granted as necessary to secure financings      and have terms of three to tenyears. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·   | our      Chief Executive Officer, current Chief Financial Officer, former Chief      Financial Officer and three other most highly compensated executive      officers based on compensation earned during  2007; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | each      director; |
|--------------------|---------------------|

| ·   | all      directors and executive officers as a  group; and |
|--------------------|-----------------------------------------------------------------|

| ·   | each      person who is known by I-trax to beneficially own 5% or more of I-trax’s      outstanding common stock. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------|

----

|     Executive Officers and      Directors*            |   | CommonStockBeneficiallyOwned |      |   | ConvertibleSecuritiesExercisableWithin60 Days** |   |      |    Total |   |   |   Percent      ofClass |   |
|---------------------------------------------------------------------------|--------|------------------------------|-----------|--------|-------------------------------------------------|--------|-----------|-------------------------|--------|--------|----------------------------------|--------|
| Frank      A. Martin                                                      |   |                         | 830,707   |   |                                            |   | 450,778   |                    |   |   | 1,281,485                        |   |   |   | 3.01 | % |
| R.      Dixon Thayer                                                      |   |                         | 45,300    |   |                                            |   | 514,373   |                    |   |   | 559,673                          |   |   |   | 1.31 | % |
| Raymond      J. Fabius, M.D.                                    |   |                         | 147,916   |   |                                            |   | 448,827   |                    |   |   | 596,743                          |   |   |   | 1.40 | % |
| David      R. Bock                                                        |   |                         | 119,693   |   |                                            |   | 475,417   |                    |   |   | 595,110                          |   |   |   | 1.40 | % |
| Haywood      D. Cochrane, Jr.                                        |   |                         | 236,626   |   |                                            |   | 306,893   |                    |   |   | 543,519                          |   |   |   | 1.28 | % |
| Yuri      Rozenfeld(1)                                                    |   |                         | 53,894    |   |                                            |   | 208,550   |                    |   |   | 262,444                          |   |   |   | *** |   |
| Philip      D. Green                                                      |   |                         | 17,800    |   |                                            |   | 82,880    |                    |   |   | 100,680                          |   |   |   | *** |   |
| Gerald      D. Mintz                                                      |   |                         | 12,000    |   |                                            |   | 40,000    |                    |   |   | 52,000                           |   |   |   | *** |   |
| Jack      A. Smith                                                        |   |                         | 8,000     |   |                                            |   | 40,000    |                    |   |   | 48,000                           |   |   |   | *** |   |
| Gail      F. Lieberman                                                    |   |                         | —   |   |                                            |   | 40,000    |                    |   |   | 40,000                           |   |   |   | *** |   |
| David      B. Nash, M.D.                                        |   |                         | —   |   |                                            |   | 40,000    |                    |   |   | 40,000                           |   |   |   | *** |   |
| Bradley      S. Wear                                                      |   |                         | —   |   |                                            |   | —   |                    |   |   | —                          |   |   |   | *** |   |
| All      executive officers and directors as a group    (12 persons) |   |                         | 1,367,043 |   |                                            |   | 2,195,634 |                    |   |   | 3,562,677                        |   |   |   | 9.28 |   |

|     5% Stockholders |   | CommonStockBeneficiallyOwned |      |   | ConvertibleSecuritiesExercisableWithin60 Days |   |    |    Total |   |   |   Percent      ofClass |   |
|-----------------------------------------|--------|------------------------------|-----------|--------|-----------------------------------------------|--------|---------|-------------------------|--------|--------|----------------------------------|--------|
| FMR      LLC(2)                         |   |                         | 4,042,079 |   |                                          |   | — |                    |   |   | 4,042,079                        |   |   |   | 9.59 | % |
| Pequot      Capital Management, Inc.(3) |   |                         | 3,144,606 |   |                                          |   | — |                    |   |   | 3,144,606                        |   |   |   | 7.46 | % |
| Ashford      Capital Management Inc.(4) |   |                         | 3,127,900 |   |                                          |   | — |                    |   |   | 3,127,900                        |   |   |   | 7.42 | % |

| *      | Executive      officers and directors of I-trax can be reached at I-trax, Inc., 4 Hillman      Drive, Suite 130, Chadds Ford, Pennsylvania 19317.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| **     | Includes      shares of common stock issuable upon exercise or conversion of options,      warrants or Series A Convertible Preferred Stock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| ***    | Less      than 1% of the outstanding shares of common stock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| (1)    | Mr. Rozenfeld      is a partner of The Spartan Group Limited Partnership (“Spartan”), an owner of      6,000 shares.  Mr. Rozenfeld has shared voting and      shared dispositive power with respect to the shares held by      Spartan.  Mr. Rozenfeld may be deemed to have beneficial      ownership of the shares held by Spartan. Mr. Rozenfeld disclaims      beneficial ownership of the shares held by Spartan, except to the extent      of his pecuniary interest in Spartan.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| (2)    | Pursuant      to a Schedule 13G filed on February 14, 2008, consists of shares      beneficially owned by FMR LLC (“FMR”) as of      December 31, 2007 as a result of acting as investment adviser to      various investment companies registered under Section 8 of the      Investment Company Act of 1940 (the ownership of one investment company,      Fidelity Small Cap Stock Fund, amounted to 2,273,463 shares) and      includes 4,042,079 shares to which FMR has sole voting power and      dispositive power. The Schedule 13G was filed jointly by FMR and      Edward C. Johnson 3d. Edward C. Johnson 3d is Chairman of      FMR.  Members of Mr. Johnson’s family are the predominant      owners of Series B shares of FMR, representing 49% of the voting      power of FMR and all Series B shareholders have entered into a      shareholders’ voting agreement under which all Series B shares will      be voted in accordance with the majority vote of Series B      shares.  As such, members of Mr. Johnson’s family may be      deemed to be members of a controlling group with respect to      FMR.  The amounts beneficially owned by FMR include      1,848,607 shares beneficially owned by Fidelity Management &      Research Company, an investment adviser registered under Section 203      of the Investment Advisers Act of 1940 and a wholly-owned subsidiary of      FMR; and 466,700 shares beneficially owned by Pyramis Global Advisors      Trust Company, a bank as defined in Section 3(a)(6) of the Securities      Exchange Act of 1934, and an indirect wholly-owned subsidiary of FMR. The      address for FMR is 82 Devonshire Street, Boston, Massachusetts      02109.  (Based on Schedule 13G/A filed by FMR with the SEC on      February 14, 2008.) |

----

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3)    | Pequot      Capital Management, Inc. (“Pequot Capital”) is an      investment adviser registered under Section 203 of the Investment      Advisers Act of 1940 and has sole voting and dispositive power with      respect to the shares it beneficially owns.  The address for      Pequot Capital is 500 Nyala Farm Road, Westport, Connecticut      06880.  (Based on Schedule 13G/A filed by Pequot Capital      Management with the SEC on February 12, 2008.)  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| (4)    | Ashford      Capital Management, Inc. (“Ashford Capital”) is an      investment adviser registered under Section 203 of the Investment      Advisers Act of 1940 and has sole voting and dispositive power with      respect to the shares it beneficially owns. The address for Ashford      Capital is 1 Walker’s Mill Road, P.O. Box 4172, Wilmington,      Delaware 19807. (Based on Schedule 13G/A filed by Ashford Capital      with the SEC on February 14,2008.) |

| Item      13. | Certain      Relationships and Related Transactions, and Director      Independence |
|---------------|-------------------------------------------------------------------------------------|

----

| Item      14. | Principal      Accounting Fees and Services |
|---------------|---------------------------------------------|

|                                |   | Fiscal      2007 |    |   | Fiscal      2006 |   |
|-------------------------------------|--------|------------------|---------|--------|------------------|--------|
|                                |   |             |    |   |             |   |
| Audit      Fees – M&P (1) |   | $                | 399,000 |   |             |   |   |
| Audit      Fees - GGK (1)           |   |             | 86,000  |   |             | $      | 502,000 |   |
| Audit-Related      Fees M&P (2) |   |             | 22,000  |   |             |   | -- |   |
| Tax      Fees                       |   |             | --      |   |             |   | -- |   |
| All      Other Fees                 |   |             | --      |   |             |   | -- |   |
| Total      Fees                     |   | $                | 507,000 |   |             | $      | 502,000 |   |

|   | (1) | Includes      fees of $200,000 and $282,000 for fiscal 2007 and 2006, respectively,      associated with the audit of I-trax’s internal controls over financial      reporting required under Section 404 of the Sarbanes-Oxley Act of      2002. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | Audit      related fees primarily include attest services related to financial      reporting that are not required by statute and regulation and accounting      consultation concerning financial accounting and reporting      standards. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Item      15. | Exhibits,      Financial Statement Schedules. |
|---------------|-----------------------------------------------|

|   | (b)      Exhibits: |
|--------|--------------------|

| Exhibit      Number | Description                                                                                                                       | Incorporated      by Reference to: |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
|                |                                                                                                                              |                               |
| 31.1                | Certification Pursuant to 18 U.S.C. Section 1350, as      Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of      2002. | Filed herewith.                    |
|                |                                                                                                                              |                               |
| 31.2                | Certification Pursuant to 18 U.S.C. Section 1350, as      Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of      2002. | Filed herewith.                    |
|                |                                                                                                                              |                               |

----

----

| Exhibit      Number | Description                                                                                                                       | Incorporated      by Reference to: |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
|                |                                                                                                                              |                               |
| 31.1                | Certification Pursuant to 18 U.S.C. Section 1350, as      Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of      2002. | Filed herewith.                    |
|                |                                                                                                                              |                               |
| 31.2                | Certification Pursuant to 18 U.S.C. Section 1350, as      Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of      2002. | Filed herewith.                    |
|                |                                                                                                                              |                               |

----